Loading…
Chinese biotech developing siRNA (RNA-interference) drugs for cardiovascular, metabolic, renal and liver diseases.
Chinese biotech developing siRNA (RNA-interference) drugs for cardiovascular, metabolic, renal and liver diseases.
Develops rather than sells drugs, so it depends on raising capital and on partner payments to fund trials. Its GalNAc technology attaches a sugar group that guides the drug to liver cells, which is why siRNA drugs from this approach mostly target liver-related conditions.
In one line: A Chinese Alnylam Pharmaceuticals (siRNA drug pioneer).
Moat: narrow (IP / patents, process know-how). Proprietary GalNAc delivery and RNAi chemistry platform built since 2007.
Headquarters: Kunshan, China · Founded: 2007 · Employees: 407
Size Suzhou Ribo Life Science (6938.HK) is a Hong Kong Health Care company (Pharmaceuticals: Generic) with a market value of $939M, the 607th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$43.18 on 6 Nov 2026.
Performance Over six months the shares fell 29.2%, against -11.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 6 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median -6.2%); the operating margin is -187.4% (peer median -16.8%).
Valuation It trades at 34.1× enterprise value to sales against a peer median of 21.8× (3rd most expensive of 6).
Capital Return on invested capital runs 106.8 points below its cost of capital (9.5% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | HK$161M | HK$155M | HK$48,620 |
| Revenue growth | — | +4% | +317,958% | — |
| Gross profit | n/a | HK$99.6M | HK$96.0M | -HK$56.5M |
| EBITDA | n/a | -HK$250M | -HK$228M | -HK$410M |
| Net income | n/a | -HK$302M | -HK$293M | -HK$473M |
| Free cash flow | n/a | -HK$331M | -HK$105M | -HK$369M |
| Capital expenditure | n/a | HK$10.7M | HK$22.5M | HK$28.3M |
| Total debt | n/a | HK$613M | HK$456M | HK$457M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Suzhou Ribo Life Science 6938.HK | $939M | -29% | +4% | -187% | 34.1× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% |
| Arrowhead Pharmaceuticals ARWR | $8.22B | -20% | +17% | -34% | 11.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6938.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.4% | -12.7% | 2nd lowest of 6 |
| 6-month return | -29.2% | -11.3% | 2nd lowest of 6 |
| Distance from 52-week high | -54.9% | -40.3% | lowest of 6 |
| Revenue growth (TTM) | +4.2% | -6.2% | 2nd highest of 6 |
| Operating margin | -187.4% | -16.8% | 2nd lowest of 5 |
| EV / Sales | 34.1× | 21.8× | 3rd most expensive of 6 |
| ROIC minus cost of capital | -106.8 pp | -7.3 pp | lowest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | 34.1× | n/a | n/a |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | 1.0× | 17.7% | -23.1% |
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | 109.3× | n/a | n/a |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | 21.8× | n/a | n/a |
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 38.3× | n/a | n/a |
| Zhejiang Shouxiangu Pharmaceutical 603896.SS | China | $398M | -22% | -10% | n/a | 3.9× | n/a | n/a |